HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishiwata, K. Articles by Senda, M. Search for Related Content PubMed PubMed Citation Articles by Ishiwata, K. Articles by Senda, M.

Re-evaluation of Amino Acid PET Studies: Can the Protein Synthesis Rates in Brain and Tumor Tissues Be Measured In Vivo?

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Department of Radiology and Nuclear Medicine, The Research Institute for Cancer and Tuberculosis, Tohoku University, Sendai, Japan
Department of Radiology and Nuclear Medicine, Research Institute for Brain and Blood Vessel-Akita, Akita, Japan

Correspondence: For correspondence or reprints contact: Dr. Kiichi Ishiwata, Positron Medical Center, Tokyo Metropolitan Institute of Gerentology, 1-1 Naka-cho, Itabeshi, Tokyo 173, Japan.

ABSTRACT

The significance of L-[methyl-¹¹C]methionine (¹¹C-Met), L-[1-¹¹C]leucine (¹¹C-Leu) and L-2-[¹⁸]fluorotyrosine (¹⁸F-Tyr) for measuring protein synthesis rates in the brain and in tumors by PET was re-evaluated. Tissue uptake and protein incorporation of ³H-Met, ¹⁴C-Leu and ¹⁸F-Tyr were investigated in mice bearing the FM3A mammary carcinoma. In the control group, the uptake of all three tracers in the brain and FM3A and their incorporation into the acid-precipitable fraction (APF) increased over 60 min. When the protein synthesis in vivo was inhibited by cycloheximide, the incorporation of all three tracers into the APF was significantly reduced to 6%–32% and 3%–11% of the control in the brain and FM3A, respectively. Under these conditions, total uptake of ¹⁴C-Leu in the brain and FM3A decreased rapidly, and most of the ¹⁴C in the APF was detected as proteins. On the other hand, ³H-Met and ¹⁸F-Tyr uptake continued to increase, and significant amounts of radioactivity were incorporated into nonprotein materials. In mice given ouabain to inhibit amino acid transport, total uptake of all three amino acids by FM3A was reduced to 67–74% of the control 5 min postinjection. These results demonstrate that uptake of the three amino acids is affected by alterations in the amino acid transport system in the brain and tumor tissues, but that only ¹⁴C-Leu uptake reflects protein synthesis rates.

This article has been cited by other articles:

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				M. A. Bredella, M. Torriani, F. Hornicek, H. A. Ouellette, W. E. Plamer, Z. Williams, A. J. Fischman, and S. R. Plotkin Value of PET in the Assessment of Patients with Neurofibromatosis Type 1 Am. J. Roentgenol., October 1, 2007; 189(4): 928 - 935. [Abstract] [Full Text] [PDF]

				W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]

				S. Ceyssens, K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans [11C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1432 - 1437. [Abstract] [Full Text] [PDF]

				W. Chen, D. H.S. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy J. Nucl. Med., June 1, 2006; 47(6): 904 - 911. [Abstract] [Full Text] [PDF]

				D S Rosenberg, G Demarquay, A Jouvet, D Le Bars, N Streichenberger, M Sindou, N Kopp, F Mauguiere, and P Ryvlin [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1686 - 1692. [Abstract] [Full Text] [PDF]

				D. Pauleit, G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H. H. Coenen, and K.-J. Langen PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in Peripheral Tumors: First Clinical Results J. Nucl. Med., March 1, 2005; 46(3): 411 - 416. [Abstract] [Full Text] [PDF]

				R. Hustinx, C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.-F. Fassotte, J. Foidart, and A. Luxen Whole-Body Tumor Imaging Using PET and 2-18F-Fluoro-L-Tyrosine: Preliminary Evaluation and Comparison with 18F-FDG J. Nucl. Med., April 1, 2003; 44(4): 533 - 539. [Abstract] [Full Text] [PDF]

				J. R. de Boer, J. Pruim, B. F.A.M. van der Laan, T. H. Que, A. T.M. Willemsen, F. W.J. Albers, and W. Vaalburg L-1-11C-Tyrosine PET in Patients with Laryngeal Carcinomas: Comparison of Standardized Uptake Value and Protein Synthesis Rate J. Nucl. Med., March 1, 2003; 44(3): 341 - 346. [Abstract] [Full Text] [PDF]

				S. Samnick, J. B. Bader, D. Hellwig, J. R. Moringlane, C. Alexander, B. F.M. Romeike, W. Feiden, and C.-M. Kirsch Clinical Value of Iodine-123-Alpha-Methyl-L-Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up J. Clin. Oncol., January 15, 2002; 20(2): 396 - 404. [Abstract] [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]